Publication | Closed Access

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

Molecular PharmacologyTherapeutic Drug MonitoringPharmacokinetic ModelingPharmacological StudyMedicineAbsolute BioavailabilityClinical PharmacologyDrug MonitoringPharmacotherapyHealthy Male SubjectsPharmacologyPharmacokineticsBi 1356Pharmacodynamic Modeling